Skip to content
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Vascular Anomalies

Long-Term Monitoring and Life with KLA

At a Glance

Kaposiform lymphangiomatosis requires individualized, lifelong follow-up even when symptoms improve. Regular blood tests, imaging, breathing and heart checks, and medication safety monitoring help detect relapse or side effects early while supporting school, work, mental health, and daily life.

Living with Kaposiform lymphangiomatosis (KLA) is a marathon, not a sprint. Because KLA is a chronic and potentially progressive condition, the focus of care shifts over time from urgent stabilization to long-term monitoring and maintaining quality of life [1][2]. While there is no single universal schedule for every patient, consistent, lifelong follow-up with a vascular anomalies team is essential [2][3].

The Nature of Stability and Relapse

It is important to understand that in KLA, “remission” often means the disease is stable and quiet, rather than gone [4].

  • Response to Treatment: Many patients see significant improvement on medications like sirolimus or trametinib, including stabilized blood counts and reduced fluid [4][5].
  • Variable Long-Term Course: The course of KLA can be unpredictable. While some patients remain stable for many years even after stopping treatment [6][7], evidence on long-term withdrawal is limited. In other cases, benefits may not be fully sustained over long periods (5+ years), or the disease may become active again [8][9]. This makes ongoing surveillance vital, even when you are feeling well.
  • Crucial Safety Warning on Tapering: Never stop, taper, or change your doses of sirolimus or trametinib without your treating team. Discontinuation can lead to severe relapse. Any trial off medication requires a deeply planned specialist decision with intensive monitoring for recurrence.

An Individualized Monitoring Framework

Your team will customize a surveillance plan based on your specific symptoms, organ involvement, sedation needs, and which medications you are taking.

1. Blood and Clotting Surveillance

Because KLA can “consume” clotting factors, regular blood tests are the backbone of monitoring.

  • Markers: Doctors typically monitor CBC/hemoglobin, PT/aPTT, platelets, fibrinogen, and D-dimer [9][8]. They will also monitor renal (kidney) and liver function, and lipids.
  • Frequency: In the early stages of treatment or during a flare, these may be checked weekly or monthly. Once stable, the interval may extend to every 3 to 6 months [3][10].

2. Thoracic and Lung Monitoring

Since KLA frequently involves the chest, keeping a close eye on the lungs and heart is a priority [11].

  • Imaging: MRI is often preferred for long-term monitoring to avoid repeated radiation [11][12], but it is not automatically the preferred test for every problem; CT, ultrasound, or echocardiography may be needed. A common research-based interval for imaging is at 12, 24, and 52 weeks after starting a new treatment, moving to once or twice a year once stable [3].
  • Functional Tests: Pulmonary Function Tests (PFTs) measure how well the lungs are working and can show improvement as the disease stabilizes [13].
  • Heart Health: If you have had fluid around the heart, or if you are taking a MEK inhibitor, regular echocardiograms (heart ultrasounds) are used to monitor heart function [14][15].

3. Medication Safety

  • Sirolimus: Requires checking “trough levels” to ensure the dose is effective but not toxic, alongside monitoring for high cholesterol, liver/kidney issues, and mouth sores [16][8].
  • MEK Inhibitors: Require medication-specific monitoring for skin rashes and, in some cases, regular eye exams to check for rare side effects affecting the retina [17][18].

Managing the Psychological Impact

The “social burden” of KLA is significant [1]. Families often deal with scan anxiety—the intense stress that occurs in the days or weeks leading up to a scheduled MRI or blood test.

To support your quality of life:

  • Integrate Mental Health: Seeking support from a counselor or psychologist who understands chronic illness can help manage the uncertainty of a rare diagnosis [1].
  • School, Work, and Daily Life: Work with your team to establish school or work accommodations. This includes developing a travel plan, planning for safe physical activities if you have bone involvement or bleeding risks, and understanding infection precautions.
  • Focus on Function: In many cases, patients see a significant improvement in their quality of life as their symptoms stabilize on treatment [16][19]. Celebrating these milestones—like returning to school or physical activities—is an important part of the journey [13].
  • Connect: Rare disease communities can provide a sense of belonging and practical advice that only another KLA family can offer [1].

While KLA requires lifelong vigilance, the goal of monitoring is to catch any changes early so that you can stay ahead of the disease and focus on living your life [20][19].

Common questions in this guide

How often are blood tests needed for KLA?
The schedule is individualized. During early treatment or a flare, tests may be done weekly or monthly; when KLA is stable, the interval may extend to every three to six months. Testing commonly checks blood counts, clotting, kidney and liver function, cholesterol, and medication levels.
What scans and heart or lung tests are used to follow KLA?
MRI is often used for long-term monitoring because it avoids repeated radiation, but CT or ultrasound may be chosen for a specific concern. Lung function tests show how well breathing works, and echocardiograms, or heart ultrasounds, check heart function when there has been fluid around the heart or a medicine such as trametinib is being used. Some teams use imaging at about 12, 24, and 52 weeks after a new treatment, then once or twice a year if the disease is stable.
Can KLA relapse after it improves?
Yes. In KLA, remission often means the disease is stable or quiet rather than gone, and treatment benefits may not last indefinitely. Never stop, taper, or change sirolimus or trametinib without the treating team; any trial off treatment requires specialist planning and close monitoring.
What safety checks are needed for KLA medicines?
Sirolimus usually requires a blood level check along with monitoring of cholesterol, liver and kidney function, and mouth sores. Medicines such as trametinib may require checks for skin rash, heart function, and eye problems, depending on the treatment plan. The treating team should explain the exact monitoring schedule.
How can I manage scan anxiety and the daily impact of KLA?
A counselor or psychologist familiar with chronic illness can help with the stress of waiting for scans and blood-test results. The care team can also help arrange school or work accommodations, travel planning, safe activity guidance, and infection precautions. Rare-disease communities may provide practical and emotional support.
How do I know which physical activities are safe with KLA?
Safe activity depends on bone involvement, bleeding risk, symptoms, and current treatment. Ask the vascular anomalies team for an individualized plan that explains which activities are appropriate and when to stop or seek help. An activity that is safe for one person with KLA may not be safe for another.

Get notified when new evidence is published on Kaposiform lymphangiomatosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (20)
  1. 1

    Kaposiform lymphangiomatosis: Diagnosis, pathogenesis, and treatment.

    McDaniel CG, Adams DM, Steele KE, et al.

    Pediatric blood & cancer 2023; (70(4)):e30219 doi:10.1002/pbc.30219.

    PMID: 36683202
  2. 2

    Multidisciplinary guidelines for initial evaluation of complicated lymphatic anomalies-expert opinion consensus.

    Iacobas I, Adams DM, Pimpalwar S, et al.

    Pediatric blood & cancer 2020; (67(1)):e28036 doi:10.1002/pbc.28036.

    PMID: 31617676
  3. 3

    Efficacy and safety of sirolimus treatment for intractable lymphatic anomalies: A study protocol for an open-label, single-arm, multicenter, prospective study (SILA).

    Ozeki M, Asada R, Saito AM, et al.

    Regenerative therapy 2019; (10()):84-91 doi:10.1016/j.reth.2018.12.001.

    PMID: 30705924
  4. 4

    Sirolimus in the treatment of kaposiform lymphangiomatosis.

    Zhou J, Yang K, Chen S, Ji Y

    Orphanet journal of rare diseases 2021; (16(1)):260 doi:10.1186/s13023-021-01893-3.

    PMID: 34103076
  5. 5

    Resolution of Refractory Chylous Effusions With Targeted MEK Inhibition in NRAS Q61R-Driven Kaposiform Lymphangiomatosis: A Case Report.

    Brown G, McNab S, Keogh S, et al.

    Case reports in pediatrics 2026; (2026()):7037459 doi:10.1155/crpe/7037459.

    PMID: 42639465
  6. 6

    Long-term low-dose sirolimus therapy and successful discontinuation in an adult with kaposiform lymphangiomatosis and disseminated intravascular coagulation: a case report.

    Liu J, Xu W, Jiang Q, Xu KF

    Frontiers in medicine 2026; (13()):1852990 doi:10.3389/fmed.2026.1852990.

    PMID: 42266937
  7. 7

    Kaposiform Lymphangiomatosis in a Male Adolescent: A Clinical Challenge and the Role of Genetics.

    Pereira-Nunes J, Madureira M, Dinis A, et al.

    Journal of investigative medicine high impact case reports 2023; (11()):23247096231166678 doi:10.1177/23247096231166678.

    PMID: 37148180
  8. 8

    Kaposiform lymphangiomatosis-the effects of long-term treatment with sirolimus: case series study and review of the literature.

    Bilny-Paluch M, Piekarczyk P, Błasińska K, et al.

    Frontiers in medicine 2026; (13()):1705297 doi:10.3389/fmed.2026.1705297.

    PMID: 42110416
  9. 9

    [Clinical characteristics of Kaposiform lymphangiomatosis: a report of 8 cases].

    Qiu T, Yang KY, Peng SH, et al.

    Zhonghua wai ke za zhi [Chinese journal of surgery] 2019; (57(12)):921-926 doi:10.3760/cma.j.issn.0529-5815.2019.12.010.

    PMID: 31826597
  10. 10

    Angiopoietins as serum biomarkers for lymphatic anomalies.

    Le Cras TD, Mobberley-Schuman PS, Broering M, et al.

    Angiogenesis 2017; (20(1)):163-173 doi:10.1007/s10456-016-9537-2.

    PMID: 27990590
  11. 11

    Imaging features of kaposiform lymphangiomatosis.

    Goyal P, Alomari AI, Kozakewich HP, et al.

    Pediatric radiology 2016; (46(9)):1282-90 doi:10.1007/s00247-016-3611-1.

    PMID: 27053281
  12. 12

    Interventional embolization for hemorrhagic pleural effusion in an infant with kaposiform lymphangiomatosis: a case report.

    Li J, Wang R, Liu C, Liu L

    Frontiers in medicine 2026; (13()):1865353 doi:10.3389/fmed.2026.1865353.

    PMID: 42597147
  13. 13

    Treatment of severe Kaposiform lymphangiomatosis positive for NRAS mutation by MEK inhibition.

    Chowers G, Abebe-Campino G, Golan H, et al.

    Pediatric research 2023; (94(6)):1911-1915 doi:10.1038/s41390-022-01986-0.

    PMID: 35246606
  14. 14

    Kaposiform lymphangiomatosis presenting with a Group A Streptococcus pericardial effusion.

    Koerner T, Patel MD, Pai V, Indramohan G

    BMJ case reports 2022; (15(3)) doi:10.1136/bcr-2021-246250.

    PMID: 35232734
  15. 15

    Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting.

    Pedersen S, Larsen KO, Christensen AH, et al.

    Acta oncologica (Stockholm, Sweden) 2022; (61(1)):45-51 doi:10.1080/0284186X.2021.1992010.

    PMID: 34666597
  16. 16

    The impact of sirolimus therapy on lesion size, clinical symptoms, and quality of life of patients with lymphatic anomalies.

    Ozeki M, Nozawa A, Yasue S, et al.

    Orphanet journal of rare diseases 2019; (14(1)):141 doi:10.1186/s13023-019-1118-1.

    PMID: 31196128
  17. 17

    Real-life efficacy and tolerance of trametinib in BRAF-rearranged low-grade gliomas: A multicenter study.

    Khouri C, Bibollet A, Bouchoucha Y, et al.

    European journal of cancer (Oxford, England : 1990) 2026; (248()):117450 doi:10.1016/j.ejca.2026.117450.

    PMID: 42858621
  18. 18

    Association of bilateral pan-uveitis with the use of trametinib for Langerhans cell histiocytosis.

    Du Y, Hu YT

    American journal of translational research 2022; (14(12)):8768-8772.

    PMID: 36628254
  19. 19

    Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease.

    Ricci KW, Hammill AM, Mobberley-Schuman P, et al.

    Pediatric blood & cancer 2019; (66(5)):e27614 doi:10.1002/pbc.27614.

    PMID: 30672136
  20. 20

    MEK Inhibition Reduces Vascular Malformations and Gene Dysregulation in NRASQ61R Human Endothelial Cells.

    Alharbi S, Wagner A, Merkle S, et al.

    Pediatric blood & cancer 2026; (73(3)):e70002 doi:10.1002/1545-5017.70002.

    PMID: 41496696

This page is for informational purposes only and does not constitute medical advice about KLA. Your vascular anomalies team should personalize monitoring, medication changes, activity guidance, and mental-health support for your situation.